,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-02-25 06:30:00,Warner Chilcott 's ( WCRX ) fourth quarter 2012 earnings (excluding special items) of 91 cents per share handsomely beat the Zacks Consensus Estimate of 73 cents.,0.9496269822120667,0.02634776011109352,0.02402527444064617,positive,0.9232792258262634
1,2013-02-25 06:30:00,"Lower selling, general & administrative costs boosted earnings in the reported quarter.",0.9461169838905334,0.026632115244865417,0.027250895276665688,positive,0.9194848537445068
2,2013-02-25 06:30:00,The company earned 96 cents per share in the final quarter of 2011.,0.07080919295549393,0.023934295400977135,0.905256450176239,neutral,0.04687489569187164
3,2013-02-25 06:30:00,"Including one-time items, fourth-quarter 2012 earnings surged 36.1% to 49 cents per share.",0.9481032490730286,0.025459744036197662,0.02643708325922489,positive,0.9226434826850891
4,2013-02-25 06:30:00,Revenues in the final quarter of 2012 declined 5% to $612 million.,0.01679435931146145,0.9732166528701782,0.00998902041465044,negative,-0.9564222693443298
5,2013-02-25 06:30:00,"The decline was primarily attributable to lower sales of its osteoporosis drug, Actonel due to generic competition.",0.018336597830057144,0.9654411673545837,0.016222244128584862,negative,-0.9471045732498169
6,2013-02-25 06:30:00,"Moreover, reduced sales of dermatological product Doryx hurt revenues in the fourth quarter of 2012.",0.017666777595877647,0.972783625125885,0.009549609385430813,negative,-0.955116868019104
7,2013-02-25 06:30:00,"Revenues, however, beat the Zacks Consensus Estimate of $564 million.",0.9139822721481323,0.05639902129769325,0.029618749395012856,positive,0.857583224773407
8,2013-02-25 06:30:00,"Full year earnings came in at $4.09 per share, well above the Zacks Consensus Estimate of $3.91 and 6.",0.8952544927597046,0.06333322823047638,0.04141217842698097,positive,0.8319212794303894
9,2013-02-25 06:30:00,8% above the year-ago earnings.,0.8253945708274841,0.09364321082830429,0.08096224069595337,positive,0.7317513823509216
10,2013-02-25 06:30:00,Full year earnings were above the guidance range of $3.75-$3.85 per share.,0.8147321939468384,0.07920254021883011,0.10606527328491211,positive,0.7355296611785889
11,2013-02-25 06:30:00,"Revenues decreased 7.4% to $2.5 billion in 2012, in line with the Zacks Consensus Estimate.",0.01715356856584549,0.9738750457763672,0.00897134654223919,negative,-0.9567214846611023
12,2013-02-25 06:30:00,Revenues from osteoporosis products declined 35.2% to $125 million.,0.017348960041999817,0.973077118396759,0.009573977440595627,negative,-0.9557281732559204
13,2013-02-25 06:30:00,Actonel sales declined 42% to $104 million.,0.017010848969221115,0.9725916385650635,0.01039739791303873,negative,-0.9555807709693909
14,2013-02-25 06:30:00,The loss of patent exclusivity of the drug in Western Europe in Dec 2010 hurt revenues in the quarter.,0.01779119297862053,0.9724001288414001,0.009808681905269623,negative,-0.9546089172363281
15,2013-02-25 06:30:00,We remind investors that Actonel was acquired from Procter & Gamble Company ( PG ) in 2009.,0.11320796608924866,0.007814921438694,0.8789771199226379,neutral,0.10539304465055466
16,2013-02-25 06:30:00,Bulk of the revenues (62.5%) came from the US market.,0.014232642948627472,0.010285770520567894,0.9754815697669983,neutral,0.003946872428059578
17,2013-02-25 06:30:00,US sales of the drug were down 40% in the fourth quarter of 2012 primarily due to a 40% decrease in filled prescriptions.,0.017367208376526833,0.9723320603370667,0.010300789959728718,negative,-0.9549648761749268
18,2013-02-25 06:30:00,"Warner Chilcott, which expects Actonel sales to continue declining, believes that osteoporosis therapy Atelvia (launched in Dec 2010) will help counter loss of revenues from Actonel in the US.",0.251186341047287,0.7012526988983154,0.04756089672446251,negative,-0.45006635785102844
19,2013-02-25 06:30:00,"Atelvia contributed $21 million to total revenue in the fourth quarter of 2012, up 10.5% sequentially.",0.949617862701416,0.015004688873887062,0.03537754714488983,positive,0.9346131682395935
20,2013-02-25 06:30:00,Revenues from oral contraceptives climbed 40.2% to $136 million.,0.9514901041984558,0.02044600248336792,0.028063826262950897,positive,0.9310441017150879
21,2013-02-25 06:30:00,Sales of Lo Loestrin FE (launched in the US in 2011) doubled to $42 million in the final quarter of 2012.,0.9250382781028748,0.013698833994567394,0.061262961477041245,positive,0.9113394618034363
22,2013-02-25 06:30:00,"Moreover, sales of Loestrin 24 FE climbed 25.4% to $89 million.",0.9584997892379761,0.020115623250603676,0.02138456143438816,positive,0.9383841753005981
23,2013-02-25 06:30:00,Sales of Loestrin 24 FE increased due to a decline in sales-related deductions and higher average selling prices.,0.9480558037757874,0.029176700860261917,0.02276748977601528,positive,0.9188790917396545
24,2013-02-25 06:30:00,An expansion in pipeline inventories also contributed to the increase in sales of Loestrin 24 FE in the final quarter of 2012.,0.9301079511642456,0.014326603151857853,0.0555654875934124,positive,0.9157813191413879
25,2013-02-25 06:30:00,"Sales of hormone therapy products climbed 15% to $61 million in the fourth quarter of 2012, driven by increased sales of Estrace cream (up 21.4% to $51 million).",0.9564370512962341,0.020489327609539032,0.02307363599538803,positive,0.9359477162361145
26,2013-02-25 06:30:00,"A 10% increase in filled prescriptions, a decline in sales-related deductions and higher average selling prices led to the rise in Estrace cream sales in the reported quarter.",0.909087061882019,0.062077559530735016,0.028835399076342583,positive,0.8470094799995422
27,2013-02-25 06:30:00,"Sales of dermatological product Doryx plummeted 59% to $19 million owing to generic competition and an increase in sales-related deductions

Sales of gastroenterology product Asacol climbed 15% to $204 million in the final quarter of 2012.",0.07777789235115051,0.9078075885772705,0.01441442221403122,negative,-0.8300297260284424
28,2013-02-25 06:30:00,Bulk of the sales (90.6%) came from the US market.,0.0148666612803936,0.010561014525592327,0.9745723605155945,neutral,0.004305646754801273
29,2013-02-25 06:30:00,"US sales of Asacol climbed 15.6% facilitated by higher average selling prices, decline in sales-related deductions and an expansion of pipeline inventories.",0.950014054775238,0.03331726789474487,0.01666863076388836,positive,0.9166967868804932
30,2013-02-25 06:30:00,Sales of urology product Enablex declined 2% to $40 million in the final quarter of 2012.,0.016670091077685356,0.9731639623641968,0.010166003368794918,negative,-0.9564938545227051
31,2013-02-25 06:30:00,"Selling, general and administrative (SG&A) expenses were down 8% in the reported quarter to $191 million.",0.016744647175073624,0.9725013375282288,0.010753967799246311,negative,-0.955756664276123
32,2013-02-25 06:30:00,"The decline was attributable to cost savings as a result of the move to the distributor model in Western Europe, reduced co-promotion expenses as a result of lower Actonel sales in ex-US markets and a reduction in the US field sales forces.",0.14912976324558258,0.8318494558334351,0.019020745530724525,negative,-0.6827197074890137
33,2013-02-25 06:30:00,Research and development (R&D) costs climbed 15% to $30 million in the fourth quarter of 2012 due to an increase in project spending.,0.9495043754577637,0.030118577182292938,0.020377114415168762,positive,0.9193857908248901
34,2013-02-25 06:30:00,"Warner Chilcott maintained the guidance for 2013, issued by it earlier in the month.",0.039281606674194336,0.009163500741124153,0.9515548944473267,neutral,0.030118105933070183
35,2013-02-25 06:30:00,The company continues to expect to earn $3.20-$3.30 per share on total revenues of $2.3-$2.4 billion in 2013.,0.41542065143585205,0.012402519583702087,0.5721768140792847,neutral,0.40301811695098877
36,2013-02-25 06:30:00,"The Zacks Consensus Estimate for 2013 is currently pegged at $3.28 per share, on revenues of $2.4 billion.",0.03133828565478325,0.008701183833181858,0.9599604606628418,neutral,0.022637102752923965
37,2013-02-25 06:30:00,Warner Chilcott currently carries a Zacks Rank #3 (Hold).,0.03437071293592453,0.019221840426325798,0.9464074373245239,neutral,0.015148872509598732
38,2013-02-25 06:30:00,Lannett Inc ( LCI ) and United Therapeutics ( UTHR ) are well placed in the pharmaceutical space with a Zacks Rank #1 (Strong Buy).,0.8466667532920837,0.0168851800262928,0.13644811511039734,positive,0.8297815918922424
39,2013-02-25 06:30:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
40,2013-02-25 06:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
